Nordhealth Ltd Due Diligence
Run due diligence on Nordhealth Ltd: check compliance and get alerts when suppliers or ownership change.
Finland · owned by Independent (Finland) · nordhealth.com · 23 vendors
Nordhealth Ltd is a Nordic-rooted healthcare software company that builds and acquires digital products for healthcare and veterinary professionals worldwide. Their software portfolio includes practice management systems, therapy platforms, and APIs used by over 13,000 clinics and hospitals. The company has been operating since 2001 and is the leading healthcare software provider in the Nordics.
Resilience scores
- Digital Sovereignty: 0
- Digital Resilience: 6
- Financial Resilience: 6
Technology vendors
- Ahrefs Pte. Ltd. — Media & Marketing — Singapore
- Google LLC — Technology — United States
- Slack Technologies, LLC — Technology — United States
- and 20 more
Services catalogue
1 service in catalogue across 1 category; runs on 23 sub-vendors.
- Supplier services
Insights
Last updated 2026-11-21 · revision 2
23 direct vendors, 244 subvendors
Direct vendors by controlling owner country (sample)
- Australia: 1
- Switzerland: 1
- United Kingdom: 1
Subvendors by controlling owner country (sample)
- Russia: 1
- Israel: 1
- Ireland: 1
Compliance
8 in-scope frameworks identified; showing 3.
GDPR (source) — Evidence found
Nordhealth Ltd is established in Finland, an EU member state, and processes personal data of individuals within the EU/EEA, making it subject to the General Data Protection Regulation.
Evidence: https://nordhealth.com/privacy/, https://nordhealth.ai/nl/privacy-security/, https://www.provet.com/blog/nordhealth-finland-receives-iso-iec-27001-certification
NIS2 (source) — No public evidence
As a healthcare SaaS provider in the EU with over 400 employees and significant revenue, Nordhealth likely falls within the scope of the NIS2 Directive as an 'essential' or 'important' entity in the health sector. Final determination depends on Finnish implementing legislation.
SOC 2 (source) — No public evidence
As a SaaS provider in the healthcare industry, customers and partners, particularly in North America, often expect a SOC 2 report as an assurance of security, availability, processing integrity, confidentiality, and privacy controls.
Financials
Three-year financials
- 2025: revenue EUR 50.84M, EBIT EUR -12.47M, equity EUR 61.56M
- 2024: revenue EUR 45.68M, EBIT EUR -7.73M, equity EUR 73.63M
- 2023: revenue EUR 36.83M, EBIT EUR -11.39M, equity EUR 82.77M
Financial Resilience Score: 6/10
Nordhealth demonstrates a mixed financial resilience profile. On the positive side, the company maintains a debt-free balance sheet with EUR 14.7M in cash at year-end 2025 (~29% of revenue), high-quality recurring SaaS revenue (~90% of total), low gross churn of 2.9%, and mission-critical positioning in veterinary and therapy practice management software. ARR reached EUR 44.0M at end of 2025 with flagship cloud products growing 24.7%. However, the company has posted persistent operating losses each year (EBIT of -11.4M, -7.7M, -12.5M for 2023-2025), with equity shrinking approximately 25% over two years from cumulative losses and buybacks. Intangible assets represent ~79% of total assets, creating impairment risk. Operating cash flow was weak at EUR 719k in 2025, and cash declined from EUR 19.6M to EUR 14.7M. The 2025 EBITDA swung back negative (-1.2M vs +3.1M in 2024) due to deliberate reinvestment in platform scalability, AI, and DACH expansion. Governance concentration with founder/family controlling ~57% of shares via dual-class structure also limits minority influence.
Key strengths: Zero debt and EUR 14.7M cash position, High recurring SaaS revenue (~90% of total), Low gross churn of 2.9% on flagship platforms, ARR growth of 8.7% (constant currency) to EUR 44.0M, Flagship cloud products ARR growth of 24.7%, Strong international expansion (UK +35.5%, US +41.7%)
Risk factors: Persistent operating losses (EBIT -12.5M in 2025), Equity base shrinking 25% over two years, Heavy goodwill/intangible exposure (~79% of total assets), Weak operating cash flow (EUR 719k in 2025), Cash declining from EUR 19.6M to EUR 14.7M year-over-year, FX risk (EUR/NOK, EUR/SEK, EUR/USD) with no hedging, Governance concentration - CEO/family control ~57% via dual-class shares, M&A execution and integration risk, Sensitive health data handling compliance risk
Revenue by geography
- Norway: 27%
- Finland: 18%
- United Kingdom: 16%
- Sweden: 12%
- Other countries: 11%
- Denmark: 9%
- DACH: 7%
Revenue by product/service
- Veterinary: 65%
- Therapy: 32%
- Other businesses: 3%
Workforce by country
- Finland: 216
- Other countries: 127
- Norway: 76
- Other Nordic countries: 45
Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.